AMRS - AMYRIS TO PARTICIPATE AT THE UBS GENOMICS 2.0 AND MEDTECH INNOVATIONS SUMMIT

PR Newswire

EMERYVILLE, Calif. , Aug. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 10, 2022 , at 3:00 pm PT / 6:00 pm ET in Dana Point, CA. Speaking on behalf of Amyris will be Sunil Chandran , Chief Science Officer and Head of Research and Development.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the company's website at https://investors.amyris.com/events-and-presentations .

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com .

Amyris, the Amyris logo, and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

SOURCE Amyris, Inc.